Nanotropil® Novo

Nanotropil® Novo is a nootropic drug with antiamnestic, psychostimulating and neurometabolic properties. Until 2020 it was produced under the name Phenotropil.
Active substance : Fonturacetam (Phenilpiracetam) , that has:

  • Stimulating action in relation to motor reactions, increasing physical performance
  • Pronounced antiamnestic effect, promotes memory consolidation, facilitates the learning process, has a positive effect on metabolic processes
  • Increases the body's resistance to stress in conditions of excessive mental and physical stress

The effect is manifested in a single dose, which is important when using the drug under extreme conditions.



Active substance: Fonturacetam (Phenylpiracetam)

Pharmachologic effect:
nootropic, antiasthenic, anticonvulsant, anxiolytic, neuromodulating.

Pharmacodynamics:
Nonotropil-novo is a nootropic possessing strong antiamnestic action. It has a direct activating effect on the integrative activity of the brain, contributes to memory consolidation, improves concentration and mental performance, facilitates the learning process, increases the speed of information transfer between the brain hemispheres and sustainability of brain tissue to hypoxia and toxic effects. Nonotropil-novo possesses anticonvulsant action and anxiolytic activity, regulates the processes of the central nervous system activation and inhibition, improves mood.
Nonotropil-novo has a positive effect on the metabolism and blood circulation of the brain, stimulates the redox processes, improves the body's energy potential due to glucose utilization. Fonturacetam increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABA receptors, does not have a noticeable effect on spontaneous bioelectric brain activity.
Nonotropil-novo has no effect on respiration and cardiovascular system, has anorexigen activity in application in course.
The stimulating effect of Nonotropil-novo is manifested in the ability to provide a moderately pronounced effect, which manifests itself in relation to motor responses, enhancing physical performance, expressed antagonism cataleptic effect of neuroleptics as well as easing the severity of hypnotic action of ethanol and hexobarbital.
Psychostimulate effect prevails in the ideational area.
Moderate inducing effect of the drug is combined with anxiolytic activity, it improves mood, has some analgesic effect by raising the pain threshold.
Adaptogenic effect is to increase the body's resistance to stress under conditions of excessive mental and physical stress, with fatigue, hypokinesia and immobilization at low temperatures.
Nonotropil-novo improves vision that is evident in the increasing severity, brightness and field of view.
Nonotropil-novo improves blood circulation of the lower limbs.
Nonotropil-novo stimulates the production of antibodies in response to the antigen, indicating that the immunostimulatory properties, but at the same time promotes immediate hypersensitivity and allergic inflammatory changes of the skin reaction induced by the introduction of the foreign protein.
After application in course - Nonotropil-novo does not develop drug dependence, tolerance, withdrawal syndrome.
The action of Nonotropil-novo is manifested in a single dose, which is important when using the drug in extreme conditions.
Nonotropil-novo has teratogenic, mutagenic, carcinogenic and embryotoxic properties. It has low toxicity, acute lethal dose of experiment is 800 mg / kg.

Pharmacokinetics:
Fonturacetam is rapidly absorbed, penetrates into the various organs and tissues, readily passes through the blood-brain barrier.
The absolute oral bioavailability of 100%.
Tmax in the blood = 1 hours,
T1/2 = 3-5 hours
Fonturacetam is not metabolized in the body.
Excreted unchanged: about 40% - in the urine and 60% - in the bile and perspiration. Indications :
CNS disorders of various origins, especially those related to cardiovascular diseases and disorders of metabolic processes in the brain, intoxication (particularly in post-traumatic conditions and phenomena of chronic cerebrovascular insufficiency), accompanied by the deterioration of intellectual-mental functions, reduction of motor activity;
neurotic conditions manifested by lethargy, increased exhaustion, decreased psychomotor activity, in violation of attention, memory impairment;
violations of the learning process;
psycho-organic syndromes that appear intellectually amnestic disorders and apathetic phenomena and apathetic state in schizophrenia.
convulsive conditions;
obesity (alimentary constitutional genesis);
prevention of hypoxia, increase resistance to stress;
correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to improve mental and physical performance;
correction of daily biorhythms, inversion of sleep-wake cycle;
chronic alcoholism (in order to reduce fatigue phenomena, depression, intellectual-mental disorders).

Contraindications:
Individual intolerance.
Precautions: Patients with severe organic lesions of the liver and kidneys, severe hypertension, with severe atherosclerosis, undergoing previously panic attacks, acute psychotic state occurring with psychomotor agitation - because of the possibility of anxiety exacerbation, panic, hallucinations and delusions, as well as patients, prone to allergic reactions to nootropics of pyrrolidone group.
Nonotropil-novo is not recommended the for children under 18 years old, during pregnancy and breastfeeding due to a lack of data on the application.

Side effects:
Insomnia (in case of taking the drug after 3p.m.)
Some patients in the first 1-3 days can have psychomotor agitation, flushing of the skin, a feeling of warmth, increased blood pressure.

Interaction:
Fonturacetam may increase the effects of drugs that stimulate the central nervous system, and nootropics.

Dosing and Administration:
Nonotropil-novo should be taken immediately after a meal. The dose and duration of treatment should be determined by a doctor. Doses vary depending on the characteristics of the patient. The average single dose is from 100 to 250 mg; average daily dose of 200 to 300 mg. The maximum permissible dose is 750 mg / day. It is recommended to take daily dose of 100 mg - once in the morning, and more than 100 mg - divided into 2 doses.
Duration of treatment may vary from 2 weeks to 3 months, on average - 30 days. If necessary, the course may be repeated after 1 month.
To improve performance - 100-200 mg once daily in the morning for 2 weeks (for athletes - 3 days).
The recommended duration of treatment for patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg 1 time a day (in the morning).
It is not recommended to take Nonotropil-novo later than 3 pm.

Overdose:
No cases of overdose were reported.

Pregnancy and breast-feeding:
Is not recommended during pregnancy and breastfeeding due to lack of clinical trial data.

Special instructions:
When excessive psycho-emotional exhaustion on the background of chronic stress and fatigue, chronic insomnia - the single dose of Nonotropil-novo can cause a sharp need for sleep during the first day. Such patients on an outpatient basis should be advised to start taking the drug in a day-off.

Manufacturer:
Valenta-Pharm, Russia



Write a review

Please login to review

Nanotropil® Novo

in Cyrillic : Нанотропил Ново
Fonturacetam (Phenilpiracetam) Fonturacetam (Phenilpiracetam)
tablets tablets

In Stock

available pack options :

100mg x 30 tablets $38.50
100mg x 10 tablets $15.00

5 reviews /
Write a review


Related Products

Actitropil®
Actitropil®
[ Fonturacetam (Phenilpiracetam) ]
In Stock

Tags: Phenotropil, Carphedon, Fonturacetam, Phenilpirecetam, Entrop, Nootropic, Нанотропил, Valenta, Actitropil